ERBB2 and breast cancer: In the BERENICE trial, the response to Pertuzumab, Trastuzumab, and common neoadjuvant anthracycline-taxane regimens for HER2+ BC tumors was evaluated; the highest pCR rate was achieved again in HER2-enriched PAM50 subtype tumors, further consolidating the notion of the increased clinical benefit of the addition of Pertuzumab to NAC + Trastuzumab in HER2+ BC treatment [27].